Excellent Outcomes After First-Line Ablation in Post-MI Patients With Tolerated VT and LVEF >35.

IF 8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Robert Rademaker, Marta de Riva, Sebastiaan R D Piers, Adrianus P Wijnmaalen, Katja Zeppenfeld
{"title":"Excellent Outcomes After First-Line Ablation in Post-MI Patients With Tolerated VT and LVEF >35.","authors":"Robert Rademaker, Marta de Riva, Sebastiaan R D Piers, Adrianus P Wijnmaalen, Katja Zeppenfeld","doi":"10.1016/j.jacep.2024.06.027","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Post-myocardial infarction (MI) patients with ventricular tachycardia (VT) are considered at risk for VT recurrence and sudden cardiac death (SCD). Recent guidelines indicate that in selected patients catheter ablation should be considered instead of an implantable cardioverter-defibrillator (ICD).</p><p><strong>Objectives: </strong>This study aimed to analyze outcomes of patients referred for VT ablation according to left ventricular ejection fraction (LVEF), tolerance of VT, and acute ablation outcome.</p><p><strong>Methods: </strong>Post-MI patients without prior ICD undergoing VT ablation at a single center between 2009 and 2022 were included. Patients who presented with tolerated VT and who had an LVEF >35% were offered catheter ablation as first-line therapy. ICD implantation was offered to all patients but was subject to shared decision according to clinical presentation, LVEF, and ablation outcome.</p><p><strong>Results: </strong>Eighty-six patients (mean age 69 ± 9 years, 84% male, mean LVEF 41 ± 9%) underwent VT ablation. In 66 patients, LVEF was >35%, of whom 51 had tolerated VT. Of these 51 patients, 37 (73%) were rendered noninducible. In 5 of 37 noninducible and in 11 of 14 inducible patients, an ICD was implanted. During a median follow-up of 40 months (Q1-Q3: 24-70 months), 10 of 86 patients had VT recurrence. The overall mortality was 27%, and 1 patient with ICD died suddenly. Among the 37 patients (none on antiarrhythmic drugs) with LVEF >35%, tolerated VT, and noninducibility, no SCD or VT recurrence occurred. Among the 14 patients with LVEF >35%, tolerated VT, and inducibility after ablation, no SCD occurred, but VT recurred in 29%.</p><p><strong>Conclusions: </strong>Post-MI patients with LVEF >35%, tolerated VT, and noninducibility after ablation have an excellent prognosis. Deferring ICD implantation seems to be safe in these patients.</p>","PeriodicalId":14573,"journal":{"name":"JACC. Clinical electrophysiology","volume":null,"pages":null},"PeriodicalIF":8.0000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Clinical electrophysiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jacep.2024.06.027","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Post-myocardial infarction (MI) patients with ventricular tachycardia (VT) are considered at risk for VT recurrence and sudden cardiac death (SCD). Recent guidelines indicate that in selected patients catheter ablation should be considered instead of an implantable cardioverter-defibrillator (ICD).

Objectives: This study aimed to analyze outcomes of patients referred for VT ablation according to left ventricular ejection fraction (LVEF), tolerance of VT, and acute ablation outcome.

Methods: Post-MI patients without prior ICD undergoing VT ablation at a single center between 2009 and 2022 were included. Patients who presented with tolerated VT and who had an LVEF >35% were offered catheter ablation as first-line therapy. ICD implantation was offered to all patients but was subject to shared decision according to clinical presentation, LVEF, and ablation outcome.

Results: Eighty-six patients (mean age 69 ± 9 years, 84% male, mean LVEF 41 ± 9%) underwent VT ablation. In 66 patients, LVEF was >35%, of whom 51 had tolerated VT. Of these 51 patients, 37 (73%) were rendered noninducible. In 5 of 37 noninducible and in 11 of 14 inducible patients, an ICD was implanted. During a median follow-up of 40 months (Q1-Q3: 24-70 months), 10 of 86 patients had VT recurrence. The overall mortality was 27%, and 1 patient with ICD died suddenly. Among the 37 patients (none on antiarrhythmic drugs) with LVEF >35%, tolerated VT, and noninducibility, no SCD or VT recurrence occurred. Among the 14 patients with LVEF >35%, tolerated VT, and inducibility after ablation, no SCD occurred, but VT recurred in 29%.

Conclusions: Post-MI patients with LVEF >35%, tolerated VT, and noninducibility after ablation have an excellent prognosis. Deferring ICD implantation seems to be safe in these patients.

可耐受 VT 且 LVEF >35 的重症肌无力患者一线消融后疗效极佳
背景:心肌梗死(MI)后室性心动过速(VT)患者被认为有VT复发和心脏性猝死(SCD)的风险。最近的指南指出,在选定的患者中,应考虑用导管消融术代替植入式心律转复除颤器(ICD):本研究旨在根据左心室射血分数(LVEF)、对 VT 的耐受性和急性消融结果分析转诊 VT 消融患者的治疗效果:方法:纳入2009年至2022年期间在一个中心接受VT消融术的既往无ICD的MI后患者。对于出现可耐受VT且LVEF>35%的患者,提供导管消融作为一线治疗。所有患者均可植入 ICD,但需根据临床表现、LVEF 和消融结果共同决定:86 名患者(平均年龄 69 ± 9 岁,84% 为男性,平均 LVEF 41 ± 9%)接受了 VT 消融术。66 名患者的 LVEF >35%,其中 51 名患者可耐受 VT。在这 51 名患者中,有 37 人(73%)无法诱发 VT。37 名非诱发患者中的 5 名和 14 名诱发患者中的 11 名植入了 ICD。在中位随访 40 个月(Q1-Q3:24-70 个月)期间,86 名患者中有 10 名患者 VT 复发。总死亡率为 27%,1 名植入 ICD 的患者突然死亡。在 LVEF >35%、可耐受 VT 且无诱发因素的 37 名患者中(无服用抗心律失常药物者),未发生 SCD 或 VT 复发。在 LVEF >35%、可耐受 VT 且消融后可诱导 VT 的 14 名患者中,未发生 SCD,但 29% 的患者 VT 复发:LVEF >35%、可耐受 VT 且消融后无诱导性的心肌梗死后患者预后良好。推迟 ICD 植入对这些患者似乎是安全的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JACC. Clinical electrophysiology
JACC. Clinical electrophysiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
10.30
自引率
5.70%
发文量
250
期刊介绍: JACC: Clinical Electrophysiology is one of a family of specialist journals launched by the renowned Journal of the American College of Cardiology (JACC). It encompasses all aspects of the epidemiology, pathogenesis, diagnosis and treatment of cardiac arrhythmias. Submissions of original research and state-of-the-art reviews from cardiology, cardiovascular surgery, neurology, outcomes research, and related fields are encouraged. Experimental and preclinical work that directly relates to diagnostic or therapeutic interventions are also encouraged. In general, case reports will not be considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信